TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07223047: A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Parti

Sponsor: Bristol-Myers Squibb · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 252 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07223047 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07223047 Rescue Dossier →